Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Ascendis Pharma A/S

Ascendis Pharma A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)130.85
  • Today's Change1.04 / 0.80%
  • Shares traded563.81k
  • 1 Year change+41.86%
  • Beta0.6571
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

  • Revenue in USD (TTM)341.08m
  • Net income in USD-444.28m
  • Incorporated2006
  • Employees879.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ionis Pharmaceuticals Inc803.07m-358.81m5.37bn927.00--8.10--6.69-2.45-2.455.504.200.2670.386410.02866,306.40-11.93-6.30-13.52-7.4498.7098.75-44.68-21.238.82--0.6587--34.105.60-35.80--11.83--
TG Therapeutics Inc264.79m-14.36m5.46bn319.00--28.43--20.62-0.1067-0.10671.741.230.57750.52343.421,002,992.00-3.13-62.87-3.91-80.0688.32---5.42-405.033.910.20970.5596--8,290.02333.86106.39------
Krystal Biotech Inc241.52m52.37m5.48bn229.00107.736.1892.1722.671.771.778.2130.800.27251.514.531,054,664.005.91-11.506.33-12.0192.55--21.68-492.857.76--0.00------107.81--39.49--
Cytokinetics, Inc.3.22m-576.40m5.79bn423.00------1,800.09-5.39-5.390.0301-0.1180.003--2.357,609.93-52.96-43.14-57.95-47.22-----17,906.24-540.47---14.271.02---92.04-24.89-35.30--9.76--
Viking Therapeutics Inc0.00-99.15m5.86bn33.00--6.43-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Blueprint Medicines Corp434.41m-128.05m5.98bn638.00--19.08--13.77-2.11-2.116.924.930.37690.89548.11663,227.50-11.11-29.92-13.84-34.0697.01---29.48-116.653.27-10.800.5525--22.2241.149.06--4.85--
Nuvalent Inc0.00-224.29m6.20bn127.00--6.01-----3.48-3.480.0015.810.00----0.00-27.79---29.25--------------0.00-------54.20------
Legend Biotech Corp (ADR)520.18m-348.13m7.54bn2.40k--6.73--14.50-1.91-1.912.856.080.2919.291,434.99288,990.60-19.47-37.71-22.25-47.1962.88---66.92-286.514.90--0.237--143.7042.15-16.11--1.57--
Madrigal Pharmaceuticals Inc76.81m-518.67m7.58bn376.00--9.75--98.66-25.07-25.073.7135.640.1172----204,289.90-79.11-62.09-100.35-74.8196.37---675.24--5.93--0.1309-------26.50--132.01--
Ascendis Pharma A/S (ADR)341.08m-444.28m7.87bn879.00------23.08-7.78-7.785.98-1.670.33290.218610.93388,032.40-43.36-47.35-93.14-53.2984.82---130.26-602.660.8448-3.121.14--421.2090.6817.45---1.61--
Tempus AI Inc640.44m-800.71m9.23bn2.30k--169.41--14.41-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Revolution Medicines Inc742.00k-567.06m9.55bn490.00--6.08--12,865.84-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exact Sciences Corp2.69bn-214.04m9.79bn6.50k--3.055,371.583.64-1.17-1.1714.7017.350.40895.4011.60414,204.30-3.25-9.71-3.58-10.6072.9674.10-7.95-28.211.93--0.4459--19.9340.6367.26---3.71--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m10.01bn20.00k24.442.6513.032.478.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Exelixis Inc2.08bn466.92m10.17bn1.31k22.694.4720.564.891.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Data as of Nov 25 2024. Currency figures normalised to Ascendis Pharma A/S's reporting currency: US Dollar USD

Institutional shareholders

70.77%Per cent of shares held by top holders
HolderShares% Held
RA Capital Management LPas of 30 Sep 20249.71m16.83%
Westfield Capital Management Co. LPas of 30 Sep 20245.13m8.90%
Avoro Capital Advisor LLCas of 30 Sep 20244.99m8.65%
Fidelity Management & Research Co. LLCas of 30 Sep 20244.55m7.89%
Artisan Partners LPas of 30 Sep 20244.41m7.64%
Janus Henderson Investors US LLCas of 30 Sep 20244.18m7.24%
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 20242.12m3.68%
Capital Research & Management Co. (International Investors)as of 30 Sep 20242.11m3.66%
Massachusetts Financial Services Co.as of 30 Sep 20241.87m3.24%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20241.77m3.06%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.